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A B S T R A C T
Background
Upper tract transitional cell carcinomas (TCC) are uncommon and aggressive tumours. There are a number of surgical approaches to
manage this condition including open radical nephroureterectomy and laparoscopic procedures.
Objectives
To determine the best surgical management option for upper tract transitional cell carcinoma.
Search methods
A sensitive search strategy was developed to identify relevant studies for inclusion in this review. The following databases were searched
for randomised trials evaluating surgical approaches to the management of upper tract TCC: Medline EMBASE, the Cochrane Central
Register of Controlled Trials (CENTRAL), CINAHL, British Nursing Index, AMED, LILACS, Web of Science®, Scopus, Biosis,
TRIP, Biomed Central, Dissertation Abstracts, and ISI Proceedings.
Selection criteria
The following criteria that were considered for this review.
Types of studies - All randomised or quasi-randomised controlled trials comparing the various surgical methods and approaches for the
management of localised upper tract transitional cell carcinoma.
Types of participants - All adult patients with localised transitional cell carcinoma. Localised disease was defined as limited to the kidney
or ureter with no gross regional lymph nodal enlargement on imaging.
Types of interventions - Any surgical method or approach for managing localised upper tract transitional cell carcinoma.
1Surgical management for upper urinary tract transitional cell carcinoma (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of outcome measures - Overall and cancer-specific survival were primary outcomes. Surgery-related morbidity. Quality of life
and health economics outcomes were secondary outcomes.
Data collection and analysis
Two review authors examined the search results independently to identify trials for inclusion.
Main results
We identified one randomised controlled trial that met our inclusion criteria. The trial showed that the laparoscopic approach had
superior peri-operative outcomes compared to open approach. Laparoscopic was superior and statistically significant for blood loss
(104 mL (millilitres) versus 430 mL, P < 0.001) and mean time to discharge (2.3 days versus 3.7, P < 0.001). Oncological outcomes
(bladder tumour-free survival, metastasis-free survival, cancer-specific survival curves), at a median follow up of 44 months and in
organ-confined disease, were comparable for both groups.
Authors’ conclusions
There is no high quality evidence available from adequately controlled trials to determine the best surgical management of upper
tract transitional cell carcinoma. However, one small randomised trial and observational data suggests that laparoscopic approach is
associated with less blood loss and early recovery from surgery with similar cancer outcomes when compared to open approach.
P L A I N L A N G U A G E S U M M A R Y
Surgery for upper tract transitional cell carcinoma
Upper tract transitional cell carcinoma is an uncommon cancer mainly affecting the draining system of the kidney (kidney pelvis) and
ureter (the tube through which urine passes from the kidney to the bladder). The main treatment approach for this condition is surgical
removal of the malignant area. There are a number of surgical techniques for this procedure and the aim of this review was to compare
them and determine which was the most effective in terms of surgical ease, patient morbidity, clinical outcome and cost. Our search
of the literature found no high quality evidence comparing different surgical techniques. Evidence from one small randomised trial
and observational studies suggests that laparoscopic surgical intervention may reduce blood loss, post-operative pain and hospital stay.
However, the quality of the evidence is poor and, therefore, it is not possible to recommend the most effective surgical procedure to
replace the existing clinical practice for managing upper tract transitional cell carcinoma.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
We performed a comprehensive search for randomised or quasi-randomised controlled trials that compared the pre-stated objectives.
Only one randomised control trial comparing laparoscopic nephroureterectomy with open nephroureterectomy was identified (Simone
2009).This trial showed that the laparoscopic approach had superior peri-operative outcomes when compared with the open approach,
which were statistically significant for blood loss (104 mL versus 430 mL; P <0.001) and mean time to discharge (2.3 days versus
3.65 days). The oncological outcome (bladder tumour free survival, metastasis free survival, cancer-specific survival curves) at a
median follow-up of 44 months, in organ confined disease, were comparable for the two groups
There were 22 comparative studies comparing various options of radical nephroureterectomy (open, laparoscopic) as shown in Table
4. Whilst they all showed better early surgical outcomes in the laparoscopic group and comparable oncological outcomes, they were
however excluded as they were all retrospective studies. Our search revealed 5 retrospective studies comparing various techniques
(open, transurethral and laparoscopic) of dealing with distal end of the ureter. We found three comparative studies between nephron
sparing surgery and nephroureterectomy and just one study comparing percutaneous management and nephroureterectomy. These
comparisons were again retrospective and were therefore excluded from the study
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Upper tract transitional cell carcinomas (TCC) are uncommon
and aggressive tumours. There are a number of surgical approaches
to manage this condition including open radical nephroureterec-
tomy and laparoscopic procedures.
Description of the condition
Upper tract transitional cell carcinoma (TCC) arises from the
renal pelvis, calyces and ureters. These tumours are uncommon
and constitute only 5% of the TCCs of the entire renal tract
(Campbell-Walsh 2003). TCCs of the renal pelvis account for
10% of all renal tumours and ureteric TCCs are even less common
(Jabbour 2000). Bilateral disease is extremely rare and occurs in
2% to 4% of the cases (Browne 2005). Although histologically
similar to bladder TCCs, upper tract transitional cell carcinoma is
a more aggressive tumour with a tendency to multifocality, local
recurrence and progression to an advanced stage (Browne 2005;
David 2002; Muntener 2007).
The risk of upper tract TCCs increases with age and commonly
occurs between the sixth and seventh decade of life. Men have
a two to three times more risk of developing upper tract TCCs
as compared to women (Campbell-Walsh 2003; David 2002).
Cigarette smoking is the most significant acquired risk factor for
upper-tract TCCs (Jensen 1988; McLaughlin 1992). Balkan en-
demic nephropathy (Petkovic 1975) (chronic tubulo-interstitial
nephritis), analgesic abuse (particularly phenacetin), exposure to
chemicals (e.g. aniline dye, coal, coke, tar, asphalt), chronic bac-
terial infection, and chemotherapy drugs (e.g., cyclophosphamide
and ifosfamide), have all been implicated (Jensen 1988; McCredie
1982).
Upper tract transitional cell carcinoma is rarely asymptomatic.
Frank or microscopic haematuria is the most common presenta-
tion followed by loin pain (Campbell-Walsh 2003). Other clin-
ical presentations include renal colic, palpable mass, weight loss,
anorexia, andbone pain.Diagnosis is based on clinical, cytological,
endoscopic and imaging grounds (Johnson 2005; Painter 2007).
Useful imaging modalities include retrograde pyelography, renal
ultrasound, computerised tomography (CT) and magnetic reso-
nance (MR) urography (Browne 2005). Stage and grade at pre-
sentation dictate prognosis, with staging being the single most im-
portant prognostic indicator (Olgac 2004).
Description of the intervention
Open nephroureterectomy (ONU) has been the standard surgi-
cal option for upper tract TCCs, with a normally functioning
contra-lateral collecting system. The procedure consists of total
nephroureterectomy, with excision of the bladder cuff around the
ureteric orifices to prevent tumour recurrence in the ureteric stump
or around the ipsilateral ureteric orifice. The procedure entails ei-
ther two incisions or a single long incision for adequate exposure.
As a result there is significant morbidity in the form post-operative
pain and therefore prolonged hospitalisation (Rassweiler 2004).
There has been considerable advancement in recent years, with the
aim of reducing post-operative pain and hospital stay, in minimal
invasive surgery. Some of the viable alternates include laparoscopic
nephroureterectomy (LNU), ureteroscopic resection/fulguration,
or percutaneous management.
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Reports have proven that LNUhas significantly reducedmorbidity
compared to ONU, although long term oncological efficacy of
LNU and ONU are similar (Arancibia 2007; Bariol 2004; Busby
2007; David 2002; Muntener 2007; Rassweiler 2004). For these
reasons LNU is steadily becoming the standard procedure of choice
for upper tract TCCs in various centres, and especially for bulky
tumours.
With the recent development of sophisticated ureteroscopes, en-
doscopic management of low-grade lesions measuring < 1.5 cm
(centimetres) with normal contralateral kidneys has been reported
in various studies to be a very favourable option (David 2002;
Johnson 2005;Mugiya 2006; Soderdahl 2005).
However, the need for long-term surveillance and patient suit-
ability are limiting factors. Laser therapy and electro-cautery are
commonly used in these settings. Adjuvant topical therapy (mito-
mycin) has been suggested to reduce recurrence of disease follow-
ing endoscopic therapy (Keeley 1997).
In some reports, the percutaneous approach combined with resec-
tion of the tumours has been suggested to be a useful option for
low-grade, large tumours (Jabbour 2000; Soderdahl 2005). For
patients with solitary, bilateral tumours, severe renal insufficiency,
and severe co-morbidities, there are three surgical options: partial
nephrectomy; segmental ureteric resection with re-anastomosis;
or ureteroscopic management (Campbell-Walsh 2003; Johnson
2005).
Furthermore, there are various techniques to deal with the lower
end of the ureter during nephroureterectomy, such as open ex-
cision, laparoscopic or endoscopic-assisted methods (Ko 2007;
Matin 2005; Romero 2007; Salvador-Bayarri 2002; Walton
2009). However, there is no consensus on the best way to deal with
it, and surgical practice remains hostage to surgeons’ preferences
and training .
How the intervention might work
Surgical excision of upper tract transitional cell carcinoma is con-
sidered the standard of care. This can be achieved either by open or
by the key-hole approach (laparoscopy). In addition, the removal
of the ureter along with a cuff of bladder is considered an essential
part of the procedure, and which may need a prior endoscopic
incision or a second open surgical incision. There are some reports
of pure endoscopic (retrograde or percutaneous) control of low-
grade upper tract transitional cell carcinoma in a selected popula-
tion (Lee 1999).
Why it is important to do this review
Upper tract transitional cell carcinoma, although relatively rare as
compared with other urological cancer, has a tendency for mul-
tifocality and aggressive behaviour (local recurrences and metas-
tases). The traditional and standard therapeutic approach of open
nephroureterectomy has been challenged by various minimally
invasive procedures, including laparoscopic surgery. Many tech-
niques are being offered for dealing with this surgically challeng-
ing problem, and it is important that an up-to-date appraisal of
literature, in the form of a systematic review, be undertaken to
inform clinical practice.
O B J E C T I V E S
To determine the best surgical management of upper tract transi-
tional cell carcinoma.
The following comparisons were pre-stated:
1. whether open radical nephroureterectomy is better than
laparoscopic nephroureterectomy;
2. whether nephroureterectomy is better than conservative
localised resection of ureter, where indicated;
3. whether open surgical resection (local or
nephroureterectomy) is better than endoscopic resection and
surveillance, where indicated;
4. whether open surgical method of handling the lower end of
the ureter is better than endoscopic or laparoscopic assisted
methods.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised or quasi-randomised controlled trials comparing
the various surgical methods and approaches for the management
of localised upper tract transitional cell carcinoma.
Types of participants
All adult patients with localised transitional cell carcinoma. Lo-
calised disease was defined as limited to the kidney or ureter, with
no gross lymph nodal enlargement on imaging.
Types of interventions
Any surgical method or approach for managing localised transi-
tional cell carcinoma of the upper urinary tract.
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Types of outcome measures
Primary outcomes
Overall and cancer-specific survival following surgical resection of
upper tract TCC using different approaches.
Secondary outcomes
Early surgical outcome
Need for re-operation
Operative complications
Post-operative morbidity / mortality
Length of operation
Length of hospital stay
Duration of catheterization
Analgesic requirement
Positive surgical margins (local resection of ureter)
Cancer outcome measures
Incidence of local recurrence or progression
Incidence of distant metastasis
Health-related quality of life (HRQOL) outcome measures
Generic HRQOL measures (e.g. SF-36, Ware 1992)
Disease-specific HRQOLmeasures (e.g.UCLA PCI, Litwin 1998)
Health economic outcome measures
Resource implications of differences in outcomes
Resource implications of differences in impact on HRQOL
Formal economic analysis (cost utility)
Length of hospital stay (days) and associated costs (in GBP)
Search methods for identification of studies
A sensitive search strategy was developed to identify relevant stud-
ies for inclusion in this review. Specific search terms were used in
conjunction with the Cochrane highly sensitive search strategy for
RCTs as described in the Cochrane Handbook for Systematic Re-
views of Interventions (designed in OVID version of MEDLINE)
(Cochrane Handbook 2009). The terms used along with the dates
for all the databases are described in ’Appendix 1’.
Data collection and analysis
A single randomised controlled trial was identified during the
search strategy. This precludes any formal meta-analysis; hence a
narrative approach was adopted to describe the study.
Selection of studies
A list of titles and abstracts of potentially relevant clinical studies
were generated by the search strategy and imported in to a bib-
liographic software (EndNote®). This list was screened by two
authors independently (BR and IE) and fully published papers
(non abstracts) were retrieved where appropriate. These papers
were further assessed to ensure they met the inclusion criteria of
this review and data extraction.
Data extraction and management
Data was extracted from each identified paper independently by
two reviewers and cross checked. The extracted data included in-
formation on trial design, participants, types of interventions, and
outcome measures. Data analyses compared radical surgery with
other primary surgical modalities and comparisons were made for
each of the outcomes. Also, comparisons were made between dif-
ferent surgical approaches
Assessment of risk of bias in included studies
Trial quality was assessed according to the method of randomisa-
tion, allocation concealment, adequate descriptions of numbers,
and reasons for patient withdrawal, as detailed in the Cochrane
Handbook for Systematic Review of Interventions.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The results of the search strategies are summarised in ’Table
1’. Of the 400 potentially relevant publications identified and
screened for retrieval, just one randomised control trial com-
paring early surgical and oncological outcomes between laparo-
scopic nephroureterectomy and open nephroureterectomy was
identified. The majority of the remaining studies were excluded,
generally due to the lack of suitability of study design or in-
tervention. Of the excluded studies thirty-one (Bariol 2004;
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Capitanio 2009; Chung 2007; Chung 2008; Dragicevic 2009;
Giannarini 2007; Gill 2000; Goel 2002; Greco 2009; Hattori
2006; Hsueh 2004; Hsueh 2007; Kawauchi 2003; Landman
2002;Li 2001 Manabe 2007; Matsui 2002; Muller 2007; Okeke
2002; Ogegawa 2006; Raman 2006; Rassweiler 2004; Stifelman
2001; Taweemonkongsap 2008; Ko 2007; Matin 2005; Romero
2007; Salvador-Bayarri 2002; Lee 1999; Lucas 2009; Walton
2009) were retrieved for detailed evaluation.
Included studies
Our review identified just one randomised control trial (Simone
2009) comparing laparoscopic nephroureterectomy with open
nephroureterectomy that met inclusion criteria. Forty patients
with non-metastatic upper tract TCC were randomised to open
nephroureterectomy and 40 patients to the laparoscopic approach.
Reported outcomes included operation times, the extent of blood
loss, hospital stay, bladder tumour-free survival, metastatic-free
survival and cancer-specific survival.
Excluded studies
A number of retrospective non-randomised studies making the
comparison between the pre-stated objectives (’Table 2’) were
identified in this study. Observational data from these studies sug-
gested that laparoscopic surgical interventions either complete or
in combination with open excision of the lower end, reduced
postoperative pain, hospital stay and resumption to normal ac-
tivities, in comparison to open surgery (Bariol 2004; Capitanio
2009; Chung 2007; Chung 2008; Gill 2000; Goel 2002; Greco
2009; Hattori 2006; Hsueh 2004; Hsueh 2007; Kawauchi 2003;
Landman 2002; Li 2001; Manabe 2007; Matsui 2002; Muller
2007; Okeke 2002; Ogegawa 2006; Raman 2006; Rassweiler
2004; Stifelman 2001; Taweemonkongsap 2008).
There were five retrospective studies identified in our search that
compared various techniques of en-bloc excision of the lower
ureter (’Table 3’). However, none of the studies showed any statis-
tically significant advantage over the other (Ko 2007;Matin 2005;
Romero 2007; Salvador-Bayarri 2002; Walton 2009).
We identified one retrospective study comparing open surgi-
cal nephroureterectomy with percutaneous approach (Lee 1999).
This study showed the disease-specific survival rates after open
and percutaneous approaches for grade 2 disease were 53.8 and
53.3 months, respectively (P > 0.05), and concluded that the per-
cutaneous approach should be an option in patients with solitary
kidneys, patients at risk of chronic renal failure, and healthy in-
dividuals with normal contra lateral kidneys who are willing to
abide by a strict and lengthy follow-up protocol.
Three studies (Dragicevic 2009; Giannarini 2007; Lucas 2009)
compared nephron sparing surgery and radical nephroureterec-
tomy (’Table 4’).
Risk of bias in included studies
The only randomised controlled trial included in this review used
stratified permuted randomisation technique with ratio of 1:1 for
treatment allocation. For risk of bias, see ’Figure 1’.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Allocation
There was no allocation concealment in the single study included
in this review. Consequently there was a high risk of reporting
bias.
Blinding
No blinding of treatment allocation, intervention or outcome as-
sessment was evident in the included trial.
Incomplete outcome data
Despite high stage and high grade tumours in ONU group, the
LNU group has worse 5 year cancer specific survival rates and 5
year metastasis free survival rates (although not statistically signif-
icant). This hasn’t been explained. The study does not give the
absolute figures for bladder tumour free rates for the two groups.
Selective reporting
The study addressed relevant immediate and oncological out-
comes.
Other potential sources of bias
Themedian follow up of this study was 41 months. Longer follow
up will be required to establish true oncological outcomes.
Effects of interventions
See: Summary of findings for the main comparison Surgical
mamgement for upper tract transitional cell carcinoma: Summary
of findings
This review identified one RCT comparing peri-operative
and oncological outcomes between laparoscopic and open
nephroureterectomy (Simone 2009). This trial was a single insti-
tutional study with all procedures (both open and laparoscopic
approaches) undertaken by one experienced surgeon. Forty pa-
tients with non-metastatic upper tract transitional cell carcinoma
were recruited for both approaches. Peri-operative outcomes were
compared using Student’s t-test and oncological outcomes were
compared using the log-rank test. Further analysis was performed
after stratification by grade and stage. This trial showed that the
laparoscopic approach had better statistically significant results for
blood loss (104 mL versus 430 mL, P < 0.001) and mean time to
discharge (2.30 days versus 3.65 days, p<0.001) when compared
to the open approach. At a median follow up of 44 months, the
overall 5 year cancer-specific survival ( 89.9% versus 79.8%) and
5 year metastasis-free survival rates (77.4% versus 72.5%) for the
open approach were better than the laparoscopic approach, respec-
tively, although not statistically significant.The bladder tumour
free rates for the two groups were similar. However, on further
stratification by stage and grade, the oncological outcomes for or-
gan-confined disease (Stage < T3) were comparable for the two
groups.
D I S C U S S I O N
Our search strategy included a comprehensive search of electronic
databases, meticulous handsearching of relevant journal articles
and abstracts and personal communication with experts in uro-
oncology. Therefore, it is highly unlikely that important studies
have been missed.
Our study found just one randomised control trial comparing
laparoscopic nephroureterectomy with open nephroureterectomy
(Simone 2009).This trial showed that the laparoscopic approach
had better perioperative outcomes when compared with the open
approach. There was statistically significant more blood loss (104
mL versus 430 mL; P < 0.001) and longer time to discharge
(2.30 days versus 3.65 days) for open surgery compared to laparo-
scopic approach, respectively. The oncological outcomes (blad-
der tumour-free survival, metastases-free survival, cancer-specific
survival ) at a median follow-up of 44 months, in pathologically
confirmed organ-confined disease were comparable for the two
groups.
We identified a number of observational studies comparing differ-
ent surgical approaches to the management of TCC. However, we
would strongly recommend caution in interpreting these results,
given the various methodological problems with the retrospective
study design, particularly the small sample sizes and their associ-
ated lack of power.
This systematic review has highlighted the paucity of good qual-
ity RCTs for surgical management of upper tact transitional cell
carcinoma. This is disappointing given that several surgical pro-
cedures (in particular minimally invasive procedures) have been
introduced over the past two decades in clinical practice with re-
ported patient-based outcomes. Observational data and one small
randomised trial, despite the small sample sizes, indicate that that
laparoscopic approach has better early surgical outcomes, and
comparable oncological outcomes in the management of upper
tract TCC (Bariol 2004; Capitanio 2009; Chung 2007; Chung
2008; Gill 2000; Goel 2002; Greco 2009; Hattori 2006; Hsueh
2004; Hsueh 2007; Kawauchi 2003; Landman 2002; Li 2001;
Manabe 2007;Matsui 2002;Muller 2007; Okeke 2002; Ogegawa
2006; Raman 2006; Rassweiler 2004; Stifelman 2001;Simone
2009 Taweemonkongsap 2008).
There are several documented problems in conducting a well de-
signed randomised controlled trial for comparing surgical inter-
ventions. With the introduction of laparoscopic approach to the
surgical excision of upper tract TCC with various reported advan-
tages, at least in the in the case series and non-randomised liter-
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ature, patients preference becomes the main issue. This is a po-
tential reason for failure to recruit enough numbers to answer the
research question.The operator’s choices or biases towards a par-
ticular procedure, which is dependent on the operator’s skill and
education, are the other impeding factors. Furthermore, blinding
of outcome assessors to the surgical procedures, especially if they
are compared, remains a subject of methodological discussion in
the surgery.
Summary of main results
In patients with localised disease, the laparoscopic approach is as-
sociated with significantly less blood loss and hospital stay which
translates into better recovery from the procedure. Short term fol-
low-up data reports no significant differences in the oncological
outcomes between laparoscopic and open approach. Clinically ef-
fectiveness of laparoscopic approach in patients with locally ad-
vanced disease (T3 and suspected nodal involvement) remains to
be proven.
Overall completeness and applicability of
evidence
In view of the poor quality of evidence, mainly from retrospective
or non-controlled studies with poor design, applicability of results
to the real clinical practice are difficult to justify. The technology
in the laparoscopic approach has disseminated faster than than the
evidence in the surgical practice and it is unlikely that results will
change the current practice.
Quality of the evidence
The overall quality of available evidence identified by this review
remains poor making it difficult to make a particular recommen-
dation for change in surgical practice of upper tract TCC.
Potential biases in the review process
The main bulk of the literature on surgical approaches in upper
tract TCC comes from uncontrolled (retrospective or prospective)
studies with inherent risks of selection and reporting biases.
Agreements and disagreements with other
studies or reviews
A recent non-systematic review reported that the laparoscopic ap-
proach was associated with a longer operating time (277 min-
utes versus 200 minutes), but reduced blood loss (241 mL versus
463 mL), a reduced analgesic requirement, and a shorter hospi-
tal stay, compared to open surgery (Rassweiler 2004). From an
oncological perspective, there was no statistically significant dif-
ferences between the two groups for bladder recurrence (24.0%
versus 24.7%), local recurrence (4.4% versus 6.3%) and distant
metastasis (15.5% versus 15.2%).The 2 and 5-year survival rates
for the laparoscopic and open groups were 75.2% versus 76.2%,
and 81.2% versus 61%, respectively (Rassweiler 2004).
A recent multicentre retrospective study of 1249 patients with
non metastatic upper tract transitional cell carcinoma compared
the oncological efficacy, i.e. recurrence rate and cancer-specific
mortality, between open and laparoscopic nephroureterectomy.
The five-year recurrence free survival estimates were 86.8% and
76.2% for LNU and ONU, respectively. Five-year cancer-specific
mortality-free survival estimates were 85.8% and 73.1% for LNU
andONU, respectively. The LNU cohort did, however, havemore
pathologically favourable cases. In a univariate adjusted analysis
to stage and also an adjusted multivariate analysis, there was no
statistical difference for recurrence and cancer specific mortality
between ONU and LNU (Capitanio 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although voluminous literature exists comparing different surgical
approaches for themanagement of upper tract TCC, the quality of
the retrospective studies and the one small randomised controlled
trial is poor. The conclusions of the reported literature support
the early benefits (less blood loss and shorter hospital stay) of the
laparoscopic approach, which is the current standard of practice
in many centres around the world. This review cannot support
any potential change in surgical practice of upper tract TCC due
to inherent biases, poor quality of design, and reporting of the
systematically reviewed studies.
Implications for research
The review has the following implications for research.
1. Future multicentre randomised controlled trials are
required to assess the benefits and harms of one surgical
approach over another in the management of upper tract TCC.
2. A consensus is needed for outcomes reporting,
standardisation of surgical technique, and introduction of newer
procedures for a disease such as upper tract TCC, where multiple
approaches have been shown to be feasible and effective.
3. Qualitative research in assessing the attitudes of patients
and physicians towards changes in surgical practice.
4. Need for randomised controlled trials in surgical treatment.
5. Research in surgical skills education and its influence on the
outcomes of procedures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Simone 2009
Methods RCT
Participants 80 patients with upper tract TCC were randomised to laparoscopic or open surgical
approach (1:1 ratio allocation)
Interventions Laparoscopic (transperitoneal) approach (n = 40) Open (two incision) approach (n =
40) All surgical procedures were performed by a single surgeon
Outcomes Operative time, blood loss, hospital stay, cancer-specific survival, bladder tumour-free
survival and metastases free survival
Notes Exclusion criteria included previous history of urothelial cancer, presence of nodal in-
volvement, distant metastasis and coexistent bladder tumour at diagnosis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes This review used stratified permuted randomisation technique
with ratio of 1:1 for treatment allocation. The power calcula-
tion was based on the primary outcome (mean time to hospital
discharge)
Allocation concealment? Unclear Therewas no allocation concealment in the single study included
in this review. Consequently there was a high risk of reporting
bias
Blinding?
All outcomes
Unclear No blinding of treatment allocation, intervention or outcome
assessment was evident in the included trial
Incomplete outcome data addressed?
All outcomes
Unclear Despite high stage and high grade tumours in ONU group, the
LNU group has worse 5 year cancer specific survival rates and
5 year metastasis free survival rates (although not statistically
significant). This hasn’t been explained. The study does not give
the absolute figures for bladder tumour free rates for the two
groups
Free of selective reporting? No The study address relevant immediate and oncological outcomes
Free of other bias? Unclear The median follow up in this study is 41 months. Longer follow
up will be required to establish true oncological outcomes
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bariol 2004 No random allocation to treatment (non-randomised trial)
Capitanio 2009 No random allocation to treatment (non-randomised trial)
Chung 2007 No random allocation to treatment (non-randomised trial)
Chung 2008 No random allocation to treatment (non-randomised trial)
David 2002 No random allocation to treatment (non-randomised trial)
Dragicevic 2009 No random allocation to treatment (non-randomised trial)
Giannarini 2007 No random allocation to treatment (non-randomised trial)
Gill 2000 No random allocation to treatment (non-randomised trial)
Goel 2002 No random allocation to treatment (non-randomised trial)
Greco 2009 No random allocation to treatment (non-randomised trial)
Hattori 2006 No random allocation to treatment (non-randomised trial)
Hsueh 2004 No random allocation to treatment (non-randomised trial)
Hsueh 2007 No random allocation to treatment (non-randomised trial)
Kawauchi 2003 No random allocation to treatment (non-randomised trial)
Ko 2007 No random allocation to treatment (non-randomised trial)
Landman 2002 No random allocation to treatment (non-randomised trial)
Lee 1999 No random allocation to treatment (non-randomised trial)
Li 2001 No random allocation to treatment (non-randomised trial)
Lucas 2009 No random allocation to treatment (non-randomised trial)
Manabe 2007 No random allocation to treatment (non-randomised trial)
Matin 2005 No random allocation to treatment (non-randomised trial)
Matsui 2002 No random allocation to treatment (non-randomised trial)
Muller 2007 No random allocation to treatment (non-randomised trial)
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(Continued)
Murphy 2002 No random allocation to treatment (non-randomised trial)
Ogegawa 2006 No random allocation to treatment (non-randomised trial)
Okeke 2002 No random allocation to treatment (non-randomised trial)
Raman 2006 No random allocation to treatment (non-randomised trial)
Rassweiler 2004 No random allocation to treatment (non-randomised trial)
Romero 2007 No random allocation to treatment (non-randomised trial)
Salvador-Bayarri 2002 No random allocation to treatment (non-randomised trial)
Stifelman 2001 No random allocation to treatment (non-randomised trial)
Taweemonkongsap 2008 No random allocation to treatment (non-randomised trial)
Walton 2009 No random allocation to treatment (non-randomised trial)
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Summary of search findings
Database Coverage Search date
July 2008
First update
December 2009
Second update
July 2010
Total no. refs
MEDLINE 1950 -> present 207 19 9 235
Premedline 22.07.08 0 0 0 0
Embase 1980 ->present 157 22 9 188
Cochrane Library No restrictions 184 5 4 193
Web of Science® 1900 -> present 411 100 33 544
AMED 1985 -> present 0 0 0 0
Cinahl 1981->present 54 24 11 89
BNI 1985 ->present 0 0 0 0
LILACS 1982-> present 2 0 0 2
Biomed Central 1997->present 35 0 3 38
BIOSIS 1926 to present 279 33 7 319
SCOPUS 1981->present 478 78 25 581
ASCO abstracts 1981 to present 6 0 1 7
Total no. refs 1813 281 102 2178
After de-duplica-
tion
1179 242 84 1505
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Table 2. Table 1. Retrospecitive non-randomised studies comparing the pre-stated objectives for open and laparoscopic
resection.
Study Surgical comparisons
Bariol 2004 Laparoscopic nephroureterectomy versus open nephroureterectomy
Capitanio 2009 Laparoscopic nephroureterectomy versus open nephroureterectomy
Chung 2007 Hand Assisted Laparoscopic nephroureterectomy versus open nephroureterectomy
Chung 2008 Hand Assisted Laparoscopic nephroureterectomy versus hand-assisted retroperitoneoscopic
nephroureterectomy
Dragicevic 2009 Open conservative surgery versus radical nephroureterectomy
Gill 2000 Laparoscopic nephroureterectomy versus open nephroureterectomy
Goel 2002 Laparoscopic nephroureterectomy versus open nephroureterectomy
Greco 2009 Laparoscopic nephroureterectomy versus open nephroureterectomy
Hattori 2006 Combined (LNU + Open bladder cuff excision) versus pure LNU (LNU + endoscopic bladder cuff
excision) versus open nephroureterectomy
Hsueh 2004 Hand-assisted Retroperitoneoscopic Laparoscopic nephroureterectomy versus open nephroureterectomy
Hsueh 2007 Hand-assisted Laparoscopic nephroureterectomy versus open nephroureterectomy
Kawauchi 2003 Hand Assisted retroperitoneoscopic nephroureterectomy versus open nephroureterectomy
Landmann 2002 Hand-assisted laparoscopic nephroureterectomy versus standard Laparoscopic nephroureterectomy
Li 2001 Hand assisted laparoscopic nephroureterectomy versus open nephroureterectomy
Lucas 2008 Nephron sparing surgery versus nephroureterectomy
Manabe 2007 Laparoscopic nephroureterectomy versus open nephroureterectomy
Matsui 2002 Retroperitoneoscopic nephroureterectomy versus open nephroureterectomy
Muller 2007 Laparoscopic nephroureterectomy versus open nephroureterectomy
Okegawa 2006 Retroperitoneoscopic nephroureterectomy versus open nephroureterectomy
Okeke 2002 Hand assisted laparoscopic nephroureterectomy versus open nephroureterectomy
Raman 2006 Hand assisted laparoscopic nephroureterectomy versus open nephroureterectomy
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Table 2. Table 1. Retrospecitive non-randomised studies comparing the pre-stated objectives for open and laparoscopic
resection. (Continued)
Rassweiler 2004 Laparoscopic nephroureterectomy versus open nephroureterectomy
Stifelman 2001 Hand Assisted Laparoscopic nephroureterectomy versus open nephroureterectomy
Taweemonkongsap 2008 Retroperitoneoscopic nephroureterectomy versus open nephroureterectomy
Romero 2007 Extravesical laparoscopic control of the bladder cuff versus extravesical open control of the bladder cuff
Ko 2007 Open excision of a bladder cuff versus transurethral incision of the ureteral orifice (TUIUO)
Salvador-Bayarri 2002 Open excision of a bladder cuff versus endoscopic resection of ureter
Matin 2005 Extravesical laparoscopic control of the bladder cuff versus cystoscopic secured detachment and ligation
method
Lee 1999 Open nephroureterectomy versus percutaneous approach
Giannarini 2007 Nephron sparing surgery versus nephroureterectomy
Walton 2009 Endoscopic ureteral detachment versus open Bladder cuff excision
Table 3. Studies comparing the various techniques of en-bloc excision of the lower ureter during nephroureterectomyprocedure.
Study Objectives Prinicpal findings
Romero 2007
Extravesical laparoscopic control of the bladder cuff
versus
Extravesical open control of the bladder cuff
· The laparoscopic group was associated with
an increase in the overall rate of recurrence and a
shorter recurrence-free survival
(not statistically significant)
· Rates of local and bladder recurrence and
distant metastases were similar
Ko 2007 Open excision of a bladder cuff
versus
Transurethral incision of the ureteral orifice (TU-
IUO)
· The bladder recurrence rates were similar
in the OC group (22.2%; 6/27) and the TUIUO
group (26.3%; 5/19)
· There were no pelvic recurrences in either
group
Salvador-Bayarri 2002 Open excision of a bladder cuff
versus
Endoscopic resection of ureter
· Bladder tumour recurrence 39% versus 34.5%
· No statistical significance
Matin 2005 Extravesical laparoscopic control of the bladder cuff
versus
Cystoscopic secured detachment and ligation
method
· Bladder tumour recurrence 41.7% versus
13.9% (not statistically significant)
· Retroperitoneal Metastasis 8.3% versus 5.6%
(not statistically significant)
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Table 3. Studies comparing the various techniques of en-bloc excision of the lower ureter during nephroureterectomyprocedure.
(Continued)
· Distant Metastasis 25% versus 8.3% (not
statistically significant)
Walton 2009 Endoscopic ureteral detachment
versus
Open Bladder cuff excision
· Bladder tumour recurrence 54.4 % versus
47.9% (not statistically significant)
· Recurrence free survival and disease specific
survival similar for both groups
Table 4. Studies comparing outcomes of nephron sparing surgery and radical nephroureterectomy
Study Objectives Findings
Giannarini 2007 Distal ureter resection with bladder cuff excision and
ureter re-implantation
versus
radical nephroureterectomy with bladder cuff excision
• Cancer specific survival at 5 and 10 years was not
statistically significantly different
(log-rank test, P = 0.896)
• Overall survival at 5 and 10 years was not
statistically significantly different
(log-rank test, P = 0.693)
Dragicevic 2009 Open conservative surgery versus Radical
nephroureterectomy
• 5 year survival rates 59% versus 55%
• 5 year survival rates for imperative and elective
indications 41% versus 75%
• Radical nephroureterectomy had statistically
significant poor outcomes for the disease on univariate
analysis
(HR = 2.2, 95% CI 1.1 to 4.6, P = 0.030)
Lucas 2008 Nephron sparing surgery versus nephroureterectomy Low grade disease
• ·5-year Overall survival 75.4% versus 66.4% P =
0.281
• ·5-year Disease Specific survival 86.2% versus
87.4% P = 0.909
High grade disease
• ·5-year overall survival 45% versus 71.5% P =
0.077
• ·5-year disease-specific survival 68.6% versus
75% P = 0.528
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A P P E N D I C E S
Appendix 1. Search stategies
Search strategies TCC
MEDLINE (OVID)
1. exp Carcinoma, Transitional Cell/
2. exp Ureteral Neoplasms/
3. ((upper tract or renal pelv$ or ureter$ or calice$) adj3 (urothelial or tcc or transitional or carcinoma$ or tumo?r$ or cancer$ or
neoplas$)).tw.
4. or/1-3
5. exp Surgery/
6. exp nephrectomy/
7. exp partial nephrectomy/
8. nephroureterectom$.tw.
9. ((ureteral or percutaneous or surgical or ureteroscopic or endoscopic) adj3 (resection or management or fulguration)).tw.
10. (ONU or LNU).tw.
11. ((radical or open or laparoscop$) adj3 (surg$ or nephro$ or nephrec)).tw.
12. partial nephrectomy.tw.
13. exp Electrocoagulation/
14. exp Laser Therapy/
15. re-anastomosis.tw.
16. electrocaut$.tw.
17. ((segmental or bladder cuff ) adj2 resection).mp.
18. or/5-17
19. 4 and 18
20. randomized controlled trial.pt.
21. controlled clinical trial.pt.
22. randomized.ab.
23. placebo.ab.
24. drug therapy.fs.
25. randomly.ab.
26. trial.ab.
27. groups.ab.
28. or/20-27
29. humans.sh.
30. 28 and 29
31. 19 and 30
Embase (OVID)
1. Transitional Cell Carcinoma/
2. exp Ureter Tumor/
3. ((upper tract or renal pelv$ or ureter$ or calice$) adj3 (urothelial or tcc or transitional or carcinoma$ or tumo?r$ or cancer$ or
neoplas$)).tw.
4. or/1-3
5. exp SURGERY/
6. exp nephrectomy/
7. exp partial nephrectomy/
8. nephroureterectom$.tw.
9. ((ureteral or percutaneous or surgical or ureteroscopic or endoscopic) adj3 (resection or management or fulguration)).tw.
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10. (ONU or LNU).tw.
11. ((radical or open or laparoscop$) adj3 (surg$ or nephro$ or nephrec)).tw.
12. partial nephrectomy.tw.
13. exp ELECTROCOAGULATION/
14. exp Low Level Laser Therapy/
15. exp Cauterization/
16. (re-anastomosis or electrocaut$).tw.
17. ((segmental or bladder cuff ) adj2 resection).tw.
18. or/5-17
19. 4 and 18
20. Crossover Procedure/
21. double-blind procedure/
22. randomized controlled trial/
23. single-blind procedure/
24. (random$ or factorial$ or crossover$ or cross over$ or placebo$ or assign$ or allocat$ or volunteer$).mp.
25. ((doubl$ or singl$) adj blind$).mp.
26. or/20-25
27. 19 and 26
Cochrane Library (Wiley)
1. MeSH descriptor Carcinoma, Transitional Cell explode all trees
2. MeSH descriptor Ureteral Neoplasms explode all trees
3. (upper tract or renal pelv* or ureter* or calice*):kw,ti,ab NEAR/3 (urothelial or tcc or transitional or carcinoma* or tumor* or
tumour* or cancer* or neoplasm*):kw,ti,ab
4. (#1 OR #2 OR #3)
5. MeSH descriptor Surgical Procedures, Operative explode all trees
6. MeSH descriptor Nephrectomy explode all trees
7. (nephrouereterectom* or nephrectom*):kw,ti,ab
8. (ureteral or percutaneous or surgical or ureteroscopic or endoscopic):kw,ti,ab NEAR/3 (resection or management or
fulguration):kw,ti,ab
9. (ONU or LNU):kw,ti,ab
10. (radical or open or laparoscop*):kw,ti,ab NEAR/3 (surg* or nephro* or nephrec*):kw,ti,ab
11. MeSH descriptor Electrocoagulation explode all trees
12. MeSH descriptor Laser Therapy explode all trees
13. re-anastomosis:kw,ti,ab OR electrocaut*:kw,ti,ab
14. (segmental or bladder cuff ):kw,ti,ab NEAR/2 (resection):kw,ti,ab
15. (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
Web of Science
1. TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR
TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
2. TS=(transitional cell carcinoma)
3. TS=(upper tract urothelial or renal pelvis or ureter or ureteral) SAME TS=(cancer* or carcinoma* or tumor* or tumour* or
neoplas*)
4. #3 OR #2
5. TS=(surgery)
6. TS=(nephroureterectomy or resection or fulguration or electro* or laser)
7. #6 OR #5
8. #7 AND #4 AND #1
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CINAHL (Ebsco)
1. (MH “Bladder Neoplasms”)
2. bladder* N3 cancer*
3. bladder* N3 neoplasm*
4. ureter* N3 neoplasm*
5. ureter* N3 cancer*
6. (transitional cell ) or tcc
7. S1 or S2 or S3 or S4 or S5 or S6
8. (MH “Surgery, Operative+”)
9. (MH “Nephrectomy”)
10. nephroureterectom* or nephrectom*
11. partial or radical or open or laparoscop*
12. resect* or fulgarat*
13. S8 or S9 or S10 or S11 or S12
14. S7 and S13
15. ( (MH “Random Assignment”) or (MH “Random Sample+”) or (MH “Crossover Design”) or (MH “Clinical Trials+”) or (MH
“Comparative Studies”) or (MH “Control (Research)+”) or (MH “Control Group”) or (MH “Factorial Design”) or (MH “Quasi-
Experimental Studies+”) or (MH “Placebos”) or (MH “Meta Analysis”) or (MH “Sample Size”) or (MH “Research, Nursing”) or
(MH “Research Question”) or (MH “Research Methodology+”) or (MH “Evaluation Research+”) or (MH “Concurrent Prospective
Studies”) or (MH “Prospective Studies”) or (MH “Nursing Practice, Research-Based”) or (MH “Solomon Four-Group Design”) or
(MH “One-Shot Case Study”) or (MH “Pretest-Posttest Design+”) or (MH “Static Group Comparison”) or (MH “Study Design”) or
(MH “Clinical Research+”) ) or ( clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or
meta?analy* or systematic review* or blind* or mask* or trial* )
16. S14 and S15
British Nursing Index (OVID)
1. exp cancer/
2. exp “Urinary System and Disorders”/
3. ((bladder$ or upper tract or renal pelv$ or ureter$ or calice$) adj3 (urothelial or tcc or transitional or carcinoma$ or tumo?r$ or
cancer$ or neoplas$)).tw.
4. 1 and 2
5. 3 or 4
6. exp surgery : operative/
7. (nephroureterectom$ or nephrectom$).tw.
8. ((ureteral or percutaneous or surgical or ureteroscopic or endoscopic) adj3 (resection or management or fulguration)).tw.
9. ((partial or radical or open or laparoscop$) adj3 (surg$ or nephro$ or nephrec)).tw.
10. 6 or 7 or 8 or 9
11. 5 and 10
12. Randomized controlled trial$.mp.
13. (clinic$ adj trial$1).tw.
14. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
15. (allocated adj2 random).tw.
16. placebo$.mp.
17. 12 or 13 or 14 or 15 or 16
18. 11 and 17
LILACS
(Transitional or Transicionales or Transição or tcc) and (surgery or surgical or cirurg$ or cirugi$ or quirúrg$ or nephrectom$ or
nefrectom$) and (Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Ab random$ OR
Ab aleator$ OR Ab placebo$ OR Mh Clinical Trials as Topic OR Ti trial)
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Biomed Central
((random* OR trial* OR blind* OR placebo*)[tw]) AND (“transitional cell carcinoma”[TW] AND (surgery OR nephrectomy OR
nephroureterectomy)[TW])
BIOSIS
1. TS= clinical trial* OR TS=research design OR TS=comparative stud* OR TS=evaluation stud* OR TS=controlled trial* OR
TS=follow-up stud* OR TS=prospective stud* OR TS=random* OR TS=placebo* OR TS=(single blind*) OR TS=(double blind*)
2. TS=(transitional cell carcinoma)
3. TS=(upper tract urothelial or renal pelvis or ureter or ureteral) SAME TS=(cancer* or carcinoma* or tumor* or tumour* or
neoplas*)
4. #2 or #3
5. TS=(surgery)
6. TS=(nephroureterectomy or resection or fulguration or electro* or laser)
7. #5 or #6
8. #1 and #4 and #7
Scopus
(TITLE-ABS-KEY(“transitional cell carcinoma”))
OR (TITLE-ABS-KEY(urothelial OR tcc OR transitional) AND (carcinoma* OR tumo*r OR cancer* OR neoplas*))
AND (TITLE-ABS-KEY(surg* OR nephrectomy OR nephroureterectomy))
AND (TITLE-ABS-KEY(random* OR trial* OR blind* OR placebo*))
AMED (OVID)
1. exp Bladder neoplasms/
2. ((bladder$ or upper tract or renal pelv$ or ureter$ or calice$) adj3 (urothelial or tcc or transitional or carcinoma$ or tumo?r$ or
cancer$ or neoplas$)).tw.
3. 1 or 2
4. exp Surgery/
5. (nephroureterectom$ or nephrectom$).tw.
6. ((ureteral or percutaneous or surgical or ureteroscopic or endoscopic) adj3 (resection or management or fulguration)).tw.
7. ((partial or radical or open or laparoscop$) adj3 (surg$ or nephro$ or nephrec)).tw.
8. 4 or 5 or 6 or 7
9. 3 and 8
10. exp Randomized controlled trials/
11. (clinic$ adj trial$1).tw.
12. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
13. (allocated adj2 random).tw.
14. placebo$.mp.
15. 10 or 11 or 12 or 13 or 14
16. 9 and 15
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